शेयर मूल्य

तारीख	ChemoCentryx शेयर मूल्य
20/10/2022	51.99 undefined
18/10/2022	51.99 undefined

तारीख	ChemoCentryx राजस्व	ChemoCentryx EBIT	ChemoCentryx लाभ
2026e	1.3 अरब undefined	885.83 मिलियन undefined	652.67 मिलियन undefined
2025e	841.57 मिलियन undefined	354.33 मिलियन undefined	261.07 मिलियन undefined
2024e	412.67 मिलियन undefined	144.57 मिलियन undefined	106.52 मिलियन undefined
2023e	224.88 मिलियन undefined	-15.02 मिलियन undefined	-15.79 मिलियन undefined
2022e	73.85 मिलियन undefined	-122.73 मिलियन undefined	-119.22 मिलियन undefined
2021	32.22 मिलियन undefined	-129.92 मिलियन undefined	-131.76 मिलियन undefined
2020	64.89 मिलियन undefined	-55.18 मिलियन undefined	-55.36 मिलियन undefined
2019	36.13 मिलियन undefined	-58.3 मिलियन undefined	-55.49 मिलियन undefined
2018	42.88 मिलियन undefined	-40.27 मिलियन undefined	-37.97 मिलियन undefined
2017	82.5 मिलियन undefined	16.49 मिलियन undefined	17.86 मिलियन undefined
2016	11.94 मिलियन undefined	-40.72 मिलियन undefined	-39.96 मिलियन undefined
2015	0 undefined	-47.69 मिलियन undefined	-47.31 मिलियन undefined
2014	0 undefined	-47.4 मिलियन undefined	-46.93 मिलियन undefined
2013	6.06 मिलियन undefined	-39.12 मिलियन undefined	-38.67 मिलियन undefined
2012	5.42 मिलियन undefined	-39.63 मिलियन undefined	-39.89 मिलियन undefined
2011	31.67 मिलियन undefined	-4.3 मिलियन undefined	-4.62 मिलियन undefined
2010	34.86 मिलियन undefined	-5.96 मिलियन undefined	-3.1 मिलियन undefined
2009	49.74 मिलियन undefined	15.7 मिलियन undefined	15.62 मिलियन undefined
2008	24.09 मिलियन undefined	-20.13 मिलियन undefined	-18.47 मिलियन undefined
2007	20.74 मिलियन undefined	-19.14 मिलियन undefined	-15.69 मिलियन undefined
2006	8.11 मिलियन undefined	-19.14 मिलियन undefined	-17.34 मिलियन undefined

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

57.1	81.6	89.5	102.7	133.3	73.4	71.3	117.8	127.3	177	172.8	436.6	264.49
35.4	12.5	0.5	1.2	0.4	0	0	30.2	51.1	2.1	0.2	0.2	0.45
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	851
1	0.6	1.3	0.6	0.6	1	0.8	0.7	1.4	2.3	1.4	4.8	3.38
93.5	94.7	91.3	104.5	134.3	74.4	72.1	148.7	179.8	181.4	174.4	441.6	269.18
1.6	2.1	1.5	1.4	1.4	1.2	0.9	0.9	1.2	1.5	3.9	52.1	57.08
8.2	1.3	6.6	16.3	16.6	41.3	5	6	7.9	0	29.5	23.8	97.86
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0
0.2	0.2	2.1	0.2	0.2	0.2	0.2	0.3	0.4	0.4	1.4	1.5	1.54
10	3.6	10.2	17.9	18.2	42.7	6.1	7.2	9.5	1.9	34.8	77.4	156.48
103.5	98.3	101.5	122.4	152.5	117.1	78.2	155.9	189.3	183.3	209.2	519	425.65

0	0	0	0	0	0	0	0	0	100	100	100	70
163.9	166.3	170.3	244.5	318.1	328.4	339.6	357	368.6	389.4	495.6	870.8	903.65
-86.6	-89.7	-94.3	-134.2	-172.9	-219.8	-267.1	-307.1	-289.2	-374.5	-430	-485.3	-617.1
0	100	0	0	0	-100	-100	-100	-100	-200	300	100	-499
0	0	0	0	0	0	0	0	0	0	0	0	0
77.3	76.7	76	110.3	145.2	108.5	72.4	49.8	79.3	14.8	66	385.7	286.12
1	0.9	0.5	0.8	0.9	0.7	0.7	0.7	1.4	1	1.5	12.9	6.75
6.2	7	4.7	6.3	5.6	7.2	4.4	8.2	7.6	12.2	18.7	19.8	26.36
6.8	3.6	3.6	3.8	0	0.3	0.5	29.4	24	51.3	38.8	12.6	10.99
0	0	0	0	0	0	0	0	0	0	0	0	0
0.4	0.3	0.5	0.5	0.3	0	0	0	0	0	0	6.3	18.92
14.4	11.8	9.3	11.4	6.8	8.2	5.6	38.3	33	64.5	59	51.6	63.02
0	0.9	11.4	0.4	0	0	0	0	4.7	19.7	19.8	18.1	4.72
0	0	0	0	0	0	0	0	0	0	0	0	0
11.8	8.5	4.8	0.3	0.2	0.2	0.2	67.6	72.4	84.5	64.2	63.6	71.8
11.8	9.4	16.2	0.7	0.2	0.2	0.2	67.6	77.1	104.2	84	81.7	76.52
26.2	21.2	25.5	12.1	7	8.4	5.8	105.9	110.1	168.7	143	133.3	139.53
103.5	97.9	101.5	122.4	152.2	116.9	78.2	155.7	189.4	183.5	209	519	425.65

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
-18	15	-3	-4	-39	-38	-46	-47	-39	17	-37	-55	-55	-131
0	0	0	0	0	0	0	0	0	0	0	1	0	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0
-5	-41	17	2	0	-3	1	-2	70	-22	44	-26	-52	16
0	1	2	3	7	8	10	9	8	8	9	10	26	36
0	0	0	0	0	0	0	0	0	0	0	1	1	2
0	0	0	0	0	0	0	0	0	0	0	0	0	0
-22	-22	17	2	-32	-33	-34	-39	39	4	16	-70	-81	-75
0	0	-1	0	0	0	0	0	0	0	0	0	-15	-19
23	-29	-27	14	-56	-31	38	33	-48	15	-53	-12	-282	92
24	-29	-26	14	-56	-31	38	34	-48	16	-52	-11	-266	111
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	10	0	0	0	0	0	4	14	0	4	-1
48	-1	0	1	57	67	2	2	8	3	10	96	355	7
47	-1	0	11	57	66	1	2	8	7	24	94	356	1
-	-	-	-	-	-	-	-	-	-	-	-1.00	-3.00	-5.00
0	0	0	0	0	0	0	0	0	0	0	0	0	0
48	-54	-9	28	-31	1	5	-3	0	28	-11	12	-6	17
-23.15	-23.18	16.47	1.88	-32.7	-33.87	-34.67	-39.55	38.85	4.16	15.6	-70.91	-96.55	-94.64
0	0	0	0	0	0	0	0	0	0	0	0	0	0

ChemoCentryx सकल मार्जिन	ChemoCentryx लाभ मार्जिन	ChemoCentryx EBIT मार्जिन	ChemoCentryx लाभ मार्जिन
2026e	99.06 %	68.35 %	50.36 %
2025e	99.06 %	42.1 %	31.02 %
2024e	99.06 %	35.03 %	25.81 %
2023e	99.06 %	-6.68 %	-7.02 %
2022e	99.06 %	-166.21 %	-161.45 %
2021	99.06 %	-403.17 %	-408.87 %
2020	99.06 %	-85.04 %	-85.31 %
2019	99.06 %	-161.36 %	-153.58 %
2018	99.06 %	-93.91 %	-88.55 %
2017	99.06 %	19.99 %	21.65 %
2016	99.06 %	-341.04 %	-334.67 %
2015	99.06 %	0 %	0 %
2014	99.06 %	0 %	0 %
2013	99.06 %	-645.54 %	-638.12 %
2012	99.06 %	-731.18 %	-735.98 %
2011	99.06 %	-13.58 %	-14.59 %
2010	99.06 %	-17.1 %	-8.89 %
2009	99.06 %	31.56 %	31.4 %
2008	99.06 %	-83.56 %	-76.67 %
2007	99.06 %	-92.29 %	-75.65 %
2006	99.06 %	-236 %	-213.81 %

तारीख	ChemoCentryx प्रति शेयर बिक्री	ChemoCentryx EBIT प्रति शेयर	ChemoCentryx प्रति शेयर लाभ
2026e	18.55 undefined	0 undefined	9.34 undefined
2025e	12.05 undefined	0 undefined	3.74 undefined
2024e	5.91 undefined	0 undefined	1.52 undefined
2023e	3.22 undefined	0 undefined	-0.23 undefined
2022e	1.06 undefined	0 undefined	-1.71 undefined
2021	0.46 undefined	-1.86 undefined	-1.89 undefined
2020	0.99 undefined	-0.84 undefined	-0.84 undefined
2019	0.63 undefined	-1.02 undefined	-0.98 undefined
2018	0.86 undefined	-0.81 undefined	-0.76 undefined
2017	1.66 undefined	0.33 undefined	0.36 undefined
2016	0.26 undefined	-0.88 undefined	-0.86 undefined
2015	0 undefined	-1.09 undefined	-1.08 undefined
2014	0 undefined	-1.1 undefined	-1.08 undefined
2013	0.15 undefined	-0.96 undefined	-0.95 undefined
2012	0.15 undefined	-1.12 undefined	-1.13 undefined
2011	0.9 undefined	-0.12 undefined	-0.13 undefined
2010	0.99 undefined	-0.17 undefined	-0.09 undefined
2009	1.41 undefined	0.45 undefined	0.44 undefined
2008	0.68 undefined	-0.57 undefined	-0.52 undefined
2007	0.59 undefined	-0.54 undefined	-0.45 undefined
2006	0.23 undefined	-0.54 undefined	-0.49 undefined

%	नाम	शेयर	परिवर्तन	तारीख
15.28770 %	Fidelity Management & Research Company LLC	1,06,78,612	48,951	30/6/2022
8.31230 %	The Vanguard Group, Inc.	58,06,227	6,86,912	30/6/2022
7.43595 %	Vifor (International), Ltd	51,94,085	0	13/9/2022
5.85740 %	BlackRock Institutional Trust Company, N.A.	40,91,453	3,06,603	30/6/2022
5.79228 %	State Street Global Advisors (US)	40,45,964	4,04,301	30/6/2022
3.42637 %	Schall (Thomas J)	23,93,352	0	13/9/2022
3.39672 %	Pictet Asset Management Ltd.	23,72,645	5,32,478	30/6/2022
3.01063 %	Wasatch Global Investors Inc	21,02,953	10,27,231	30/6/2022
2.56640 %	Baker Bros. Advisors LP	17,92,657	8,75,795	30/6/2022
2.20022 %	GW&K Investment Management, LLC	15,36,877	3,75,530	30/6/2022
2.04006 %	Cormorant Asset Management, LP	14,25,000	5,60,000	30/6/2022
2.01064 %	Invesco Advisers, Inc.	14,04,451	34,143	30/6/2022
1.91375 %	Hood River Capital Management LLC	13,36,776	13,36,776	30/6/2022
1.68780 %	Marshall Wace LLP	11,78,948	-2,19,635	30/6/2022
1.57453 %	Norges Bank Investment Management (NBIM)	10,99,824	6,61,000	31/12/2021
1.57102 %	HealthCor Management, L.P.	10,97,370	1,40,630	30/6/2022
1.44155 %	Geode Capital Management, L.L.C.	10,06,934	6,519	30/6/2022
1.20670 %	Nuveen LLC	8,42,891	3,40,858	30/6/2022
1.04277 %	Eventide Asset Management, LLC	7,28,385	0	30/6/2022
0.94917 %	Morgan Stanley & Co. LLC	6,63,007	2,62,249	30/6/2022
0.91145 %	Sofinnova Investments, Inc	6,36,659	62,975	30/6/2022
0.85897 %	Logos Global Management LLC	6,00,000	6,00,000	30/6/2022
0.83184 %	Wellington Management Company, LLP	5,81,050	-64,783	30/6/2022
0.82179 %	Integral Health Asset Management, LLC	5,74,029	1,74,029	30/6/2022
0.79355 %	Principal Global Investors (Equity)	5,54,300	2,49,434	30/6/2022
0.78175 %	Barclays Bank PLC	5,46,057	5,05,367	30/6/2022
0.78099 %	Tri Locum Partners LP	5,45,532	2,49,205	30/6/2022
0.70514 %	Northern Trust Investments, Inc.	4,92,544	46,115	30/6/2022
0.69505 %	APG Asset Management N.V.	4,85,501	4,85,501	31/3/2022
0.63232 %	Perceptive Advisors LLC	4,41,680	-12,13,399	30/6/2022
0.54723 %	Charles Schwab Investment Management, Inc.	3,82,244	14,545	30/6/2022
0.53069 %	Millennium Management LLC	3,70,692	-9,30,257	30/6/2022
0.51866 %	Voloridge Investment Management, LLC	3,62,291	-3,01,944	30/6/2022
0.45346 %	Invesco Capital Management LLC	3,16,743	76,060	30/6/2022
0.44846 %	Goldman Sachs & Company, Inc.	3,13,253	62,366	30/6/2022
0.44399 %	T. Rowe Price Associates, Inc.	3,10,129	-55,505	30/6/2022
0.43582 %	Citadel Advisors LLC	3,04,424	-1,906	30/6/2022
0.40604 %	Raymond James & Associates, Inc.	2,83,620	-11,213	30/6/2022
0.37153 %	Raymond James Financial Services Advisors, Inc.	2,59,519	12,347	30/6/2022
0.33152 %	PGIM Quantitative Solutions LLC	2,31,570	2,31,570	30/6/2022
0.32847 %	Parametric Portfolio Associates LLC	2,29,439	-14,171	30/6/2022
0.32073 %	Kanaya (Susan M)	2,24,034	0	13/9/2022
0.31592 %	Thornburg Investment Management, Inc.	2,20,675	-25,602	30/6/2022
0.27986 %	Dimensional Fund Advisors, L.P.	1,95,488	-1,24,852	30/6/2022
0.26477 %	Lisanti Capital Growth, LLC	1,84,946	-1,36,623	30/6/2022
0.25810 %	Lord, Abbett & Co. LLC	1,80,285	1,69,409	30/6/2022
0.25803 %	BNY Mellon Asset Management	1,80,238	21,793	30/6/2022
0.25394 %	BlackRock Investment Management, LLC	1,77,382	7,809	30/6/2022
0.24105 %	BlackRock Financial Management, Inc.	1,68,375	22,142	30/6/2022
0.24086 %	Granahan Investment Management, Inc.	1,68,245	45,478	30/6/2022
0.24071 %	Two Sigma Investments, LP	1,68,141	-8,33,794	30/6/2022
0.23595 %	Goldman Sachs Asset Management, L.P.	1,64,816	39,130	30/6/2022
0.22906 %	Altium Capital Management LP	1,60,000	1,60,000	30/6/2022
0.22824 %	Citi Investment Research (US)	1,59,427	1,17,029	30/6/2022
0.22104 %	Soleus Capital Management, L.P.	1,54,400	1,54,400	30/6/2022
0.22069 %	Susquehanna International Group, LLP	1,54,151	-18,198	30/6/2022
0.21813 %	Rafferty Asset Management LLC	1,52,368	-73,036	30/6/2022
0.21206 %	Feczko (Joseph M)	1,48,127	0	13/9/2022
0.20516 %	Edwards (Thomas A)	1,43,306	0	13/9/2022
0.20438 %	Parker (Geoffrey M)	1,42,763	0	13/9/2022
0.19931 %	Assenagon Asset Management S.A.	1,39,219	-22,556	30/6/2022
0.19590 %	Northern Trust Global Investments	1,36,838	38,823	30/6/2022
0.19570 %	Nomura Asset Management Co., Ltd.	1,36,700	-59,499	30/11/2021
0.19361 %	BofA Global Research (US)	1,35,237	-1,11,166	30/6/2022
0.19327 %	BZ Bank AG (Asset Management)	1,35,000	0	31/5/2022
0.18897 %	Schweizerische Nationalbank	1,32,000	16,100	30/6/2022
0.17623 %	Medical Strategy GmbH	1,23,100	7,500	31/5/2022
0.17337 %	International Biotechnology Trust PLC	1,21,100	85,000	30/6/2022
0.17000 %	Allspring Global Investments, LLC	1,18,744	39,199	30/6/2022
0.16298 %	Capital Fund Management S.A.	1,13,844	1,13,844	30/6/2022
0.15050 %	ExodusPoint Capital Management, LP	1,05,124	11,155	30/6/2022
0.13850 %	Ensign Peak Advisors, Inc.	96,746	23,783	30/6/2022
0.13522 %	Mutual of America Capital Management LLC	94,450	-41,248	30/6/2022
0.13505 %	UBS Financial Services, Inc.	94,337	-73,833	30/6/2022
0.12737 %	Aperio Group, LLC	88,969	-6,250	30/6/2022
0.12549 %	Cappel (Markus J)	87,658	0	13/9/2022
0.12277 %	BlackRock Advisors (UK) Limited	85,759	5,091	31/8/2022
0.12262 %	Mirabella Financial Services LLP	85,653	85,653	30/6/2022
0.11811 %	Rhumbline Advisers Ltd. Partnership	82,501	8,950	30/6/2022
0.11544 %	Group One Trading, L.P.	80,635	80,635	30/6/2022
0.11195 %	Tekla Capital Management LLC	78,197	0	30/6/2022
0.10809 %	AllianceBernstein L.P.	75,500	13,100	30/6/2022
0.10705 %	California State Teachers Retirement System	74,776	9,871	30/6/2022
0.10652 %	BlackRock Asset Management Ireland Limited	74,403	9,221	30/6/2022
0.10436 %	Jane Street Capital, L.L.C.	72,896	-41,935	30/6/2022
0.10415 %	McKinnell (Henry A Jr)	72,749	7,726	20/5/2022
0.10340 %	Allianz Global Investors U.S. LLC	72,225	7,540	30/6/2022
0.09947 %	Jump Financial, LLC	69,484	60,484	30/6/2022
0.09786 %	Cahill Wealth Management, LLC	68,358	23,445	30/6/2022
0.09306 %	Hudson Bay Capital Management LP	65,000	10,000	30/6/2022
0.09105 %	Cubist Systematic Strategies, LLC	63,599	31,059	30/6/2022
0.09047 %	EFG Asset Management (UK) Limited	63,195	11,721	31/5/2022
0.08883 %	EFG Asset Management (North America) Corp	62,051	8,550	30/6/2022
0.08757 %	Ohio Public Employees Retirement System	61,171	26,172	30/6/2022
0.08715 %	Algert Global LLC	60,875	46,740	30/6/2022
0.08332 %	Jennison Associates LLC	58,200	58,200	30/6/2022
0.07855 %	State of Wisconsin Investment Board	54,866	-11,834	30/6/2022
0.07526 %	SEI Investments Management Corporation	52,572	52,572	30/6/2022
0.07434 %	PanAgora Asset Management Inc.	51,929	23,495	30/6/2022
0.07300 %	Legal & General Investment Management Ltd.	50,994	8,111	30/6/2022

नाम	रिश्ता	द्विसप्ताह सहसंबंध	एकमासिक सहसंबंध	त्रैमासिक सहसंबंध	छह महीने का सहसंबंध	वार्षिक सहसंबंध	द्विवार्षिक सहसंबंध
Thermo Fisher Scientific	आपूर्तिकर्ताग्राहक	0,93	0,49	0,55	0,76	0,80	-0,48
Vifor Pharma	आपूर्तिकर्ताग्राहक	0,04	0,26	-0,66	-0,62	0,03	-0,33

What values and corporate philosophy does ChemoCentryx represent?

ChemoCentryx Inc represents a strong commitment to scientific innovation, a focus on patient needs, and a dedication to improving the lives of individuals with serious diseases. The company's corporate philosophy revolves around developing novel therapies that target the chemokine system, aiming to address unmet medical needs. With their extensive research and development efforts, ChemoCentryx Inc aims to provide effective treatments in areas such as autoimmune diseases, cancer, and inflammatory disorders. By leveraging their expertise in chemokine biology, they strive to make a positive impact on patient outcomes and contribute to the advancement of healthcare.

In which countries and regions is ChemoCentryx primarily present?

ChemoCentryx Inc has a primary presence in various countries and regions. The company operates primarily in the United States, where its headquarters is located. Additionally, ChemoCentryx Inc maintains a strong presence in other parts of North America. It also extends its reach to Europe, including countries like Germany, France, and the United Kingdom. Furthermore, ChemoCentryx Inc has a growing presence in Asia, with a focus on countries such as China and Japan. With its global presence, the company is strategically positioned to serve and expand its customer base in these key markets.

What significant milestones has the company ChemoCentryx achieved?

Some significant milestones achieved by ChemoCentryx Inc include the successful completion of multiple clinical trials for their drug candidates, obtaining regulatory approvals for specific treatments, and securing partnerships with other pharmaceutical companies. Additionally, ChemoCentryx Inc has demonstrated positive results in improving patient outcomes and quality of life through their innovative therapies. Notable milestones also include the company's growth and expansion in the pharmaceutical industry, as well as their commitment to advancing research and development efforts in the field of inflammatory and autoimmune diseases.

What is the history and background of the company ChemoCentryx?

ChemoCentryx Inc is a biopharmaceutical company with a rich history and background. Founded in 1997, the company is focused on developing innovative solutions for inflammatory and autoimmune diseases. ChemoCentryx has established itself as a leader in the field of chemokine-based therapeutics, leveraging its deep understanding of the chemokine system to discover and develop potent drugs. Over the years, ChemoCentryx has successfully advanced multiple clinical programs, earning recognition for its groundbreaking research in the treatment of various conditions including rare renal diseases and immune-mediated disorders. With a dedicated team of experts and a commitment to improving patient lives, ChemoCentryx continues to make significant contributions to the pharmaceutical industry.

Who are the main competitors of ChemoCentryx in the market?

The main competitors of ChemoCentryx Inc in the market include top pharmaceutical companies such as Pfizer, Inc., Novartis AG, and AstraZeneca PLC. These companies specialize in the development and commercialization of innovative drugs and therapies in various therapeutic areas, including immunology and inflammation. ChemoCentryx Inc aims to differentiate itself by focusing on the discovery and development of new medications targeting specific chemokine and chemoattractant receptors. Through its unique approach and collaborative efforts with research partners, ChemoCentryx Inc strives to create effective treatments for patients with rare and serious diseases.

In which industries is ChemoCentryx primarily active?

ChemoCentryx Inc is primarily active in the biotechnology industry.

What is the business model of ChemoCentryx?

ChemoCentryx Inc is a biopharmaceutical company with a business model that focuses on the discovery, development, and commercialization of orally-administered medicines. The company primarily aims to develop treatments for immune-inflammatory diseases, autoimmune disorders, and cancer. ChemoCentryx Inc is known for its expertise in targeting the chemokine system, a network of molecules involved in various inflammatory processes. Through its research and development efforts, the company strives to deliver innovative therapies that address unmet medical needs and improve patients' lives. ChemoCentryx Inc's business model centers around advancing its pipeline of drug candidates and partnering with pharmaceutical companies to bring these potential treatments to market.

ChemoCentryx 2025 की कौन सी KGV है?

ChemoCentryx का केजीवी 13.91 है।

ChemoCentryx 2025 की केयूवी क्या है?

ChemoCentryx KUV 4.32 है।

ChemoCentryx का AlleAktien गुणवत्ता स्कोर क्या है?

ChemoCentryx के लिए AlleAktien गुणवत्ता स्कोर 4/10 है।

ChemoCentryx 2025 का वार्षिक कारोबार कितना है?

अपेक्षित ChemoCentryx का व्यापार वोल्यूम 841.57 मिलियन USD है।

ChemoCentryx 2025 का लाभ कितना है?

अपेक्षित ChemoCentryx लाभ 261.07 मिलियन USD है।

ChemoCentryx क्या करता है?

ChemoCentryx Inc. is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of autoimmune diseases, inflammation, and cancer. It was founded in California in 1997 and is currently headquartered in San Carlos. The company's business model includes research and development of new drugs, focusing on the identification and study of chemokines involved in various diseases. These chemokines are targeted to achieve therapeutic effects. An example of such a drug is Avacopan, currently in Phase III clinical trials for the treatment of ANCA-associated vasculitis (AAV), a rare autoimmune disease causing inflammation in small blood vessels. Avacopan aims to block the chemokine receptor C5a, which triggers the inflammatory response. ChemoCentryx also forms partnerships with other companies in the pharmaceutical industry to advance its research and development, such as the collaboration with Vifor Pharma for the development and marketing of Avacopan in Europe. In addition to research and development, ChemoCentryx has a clinical development department conducting clinical trials to assess the efficacy and safety of its developed drugs and prepare for FDA or EMA approval. Intellectual property protection is also an important aspect of ChemoCentryx's business model, with several patents on its technologies and drugs to prevent imitation. Overall, ChemoCentryx has a promising business model based on discovering and developing innovative drugs for the treatment of severe diseases. Its goal, supported by a secure financial base and dedicated employees, is to continue developing medications that contribute to improving patients' health.

ChemoCentryx डिविडेंड कितना है?

ChemoCentryx एक वर्ष में बार वितरण करते हुए 0 USD का डिविडेंड देता है।

ChemoCentryx कितनी बार लाभांश देती है?

वर्तमान में ChemoCentryx के लिए डिविडेंड की गणना नहीं की जा सकती है या फिर कंपनी डिविडेंड नहीं दे रही है।

ChemoCentryx ISIN क्या है?

ChemoCentryx का ISIN US16383L1061 है।

ChemoCentryx WKN क्या है?

ChemoCentryx का WKN A0NBM2 है।

ChemoCentryx टिकर क्या है?

ChemoCentryx का टिकर CCXI है।

ChemoCentryx कितना लाभांश देती है?

पिछले 12 महीनों में ChemoCentryx ने का डिविडेंड भुगतान किया। यह लगभग के डिविडेंड यील्ड के बराबर है। आगामी 12 महीनों के लिए ChemoCentryx अनुमानतः 0 USD का डिविडेंड भुगतान करेगी।

ChemoCentryx का डिविडेंड यील्ड कितना है?

ChemoCentryx का वर्तमान डिविडेंड यील्ड है।

ChemoCentryx कब लाभांश देगी?

ChemoCentryx तिमाही आधार पर लाभांश का भुगतान करता है। यह महीनों में वितरित किया जाता है।

ChemoCentryx का लाभांश कितना सुरक्षित है?

ChemoCentryx ने पिछले 0 वर्षों में हर साल डिविडेंड का भुगतान किया।

ChemoCentryx का लाभांश कितना है?

आने वाले 12 महीनों के लिए 0 USD के डिविडेंड की उम्मीद की जा रही है। यह 0 % के डिविडेंड यील्ड के बराबर है।

ChemoCentryx किस सेक्टर में है?

ChemoCentryx को 'स्वास्थ्य' क्षेत्र से संबद्ध किया गया है।

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

ChemoCentryx का आखिरी लाभांश प्राप्त करने के लिए, जो 29/8/2025 को 0 USD की राशि में था, आपको Ex-दिन 29/8/2025 से पहले इसे अपनी डिपो में रखना आवश्यक था।

ChemoCentryx ने आखिरी बार लाभांश कब भुगतान किया था?

अंतिम लाभांश का भुगतान 29/8/2025 को किया गया था।

ChemoCentryx का लाभांश 2024 में कितना था?

2024 में ChemoCentryx द्वारा 0 USD डिविडेंड के रूप में वितरित किए गए थे।

ChemoCentryx डिविडेंड किस मुद्रा में वितरित करता है?

ChemoCentryx के दिविडेंड USD में वितरित किए जाते हैं।

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022e	2023e	2024e	2025e	2026e
0.01	0.02	0.02	0.05	0.03	0.03	0.01	0.01	0	0	0.01	0.08	0.04	0.04	0.06	0.03	0.07	0.22	0.41	0.84	1.3
-	150.00	20.00	104.17	-30.61	-8.82	-83.87	20.00	-	-	-	645.45	-48.78	-14.29	77.78	-50.00	128.13	206.85	83.93	104.13	54.10
387.50	155.00	129.17	63.27	91.18	100.00	620.00	516.67	-	-	281.82	37.80	73.81	86.11	48.44	96.88	42.47	13.84	7.52	3.69	2.39
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	31	0	0	0	0	0
-17	-15	-18	15	-3	-4	-39	-38	-46	-47	-39	17	-37	-55	-55	-131	-119	-15	106	261	652
-	-11.76	20.00	-183.33	-120.00	33.33	875.00	-2.56	21.05	2.17	-17.02	-143.59	-317.65	48.65	-	138.18	-9.16	-87.39	-806.67	146.23	149.81
35.25	35.25	35.25	35.25	35.25	35.25	35.41	40.92	43.28	43.89	46.43	49.62	49.81	56.9	65.69	69.85	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

बाजार	ChemoCentryx टिकर
डसेलडोर्फ	2CX.DU
फ्रैंकफर्ट	2CX.F
म्यूनिख	2CX.MU
NASDAQ	CCXI
SIX	2CX.SW

ChemoCentryx टिकर	ChemoCentryx FIGI
CCXIEUR:XB	BBG00JNKCFR2
CCXIEUR:XS	BBG00JNKCG63
CCXIUSD:XB	BBG00JPVRB53
CCXIUSD:XS	BBG00JPVRBM4

किंवदंती निवेशक Eulerpool पर भरोसा करते हैं

ChemoCentryx शेयर CCXI

शेयर मूल्य

शेयर मूल्य

टिकरCCXI

ISINUS16383L1061

WKNA0NBM2

ChemoCentryx शेयर कीमत

कुर्स

अवलोकन

इंट्राडे सुविधा

कुल रिटर्न और सापेक्षिक मूल्य परिवर्तन

व्याख्या और निवेश

ChemoCentryx शेयर मूल्य इतिहास

ChemoCentryx शेयर बिक्री, EBIT, लाभ

उमसात्ज, गेविन्न & EBIT

उमसात्ज, EBIT और आय की समझ

सालाना विश्लेषण और तुलनाएँ

निवेश के लिए उम्मीदें उपयोग करें

निवेश संविधान

ChemoCentryx बिक्री, लाभ और ईबीआईटी इतिहास

ChemoCentryx शेयर मापदंड

गुआव

आय और विकास

सकल मार्जिन

EBIT और EBIT-मार्जिन

आय और विकास

शेयर बकाया

वार्षिक तुलना की व्याख्या

अपेक्षाएँ और अनुमान

बिलान्ज

बिलान्ज की समझ

संपत्तियाँ

दायित्व

मालिकाना हक

वर्ष-दर-वर्ष विश्लेषण

डेटा की व्याख्या

ChemoCentryx शेयर मार्जिन

मार्जिन

ब्रूटोमार्जिन की समझ

EBIT मार्जिन विश्लेषण

उम्सात्झ्मार्जिन अंतर्दृष्टि

अपेक्षाओं की व्याख्या

तुलनात्मक विश्लेषण

ChemoCentryx मार्जिन इतिहास

ChemoCentryx शेयर बिक्री, EBIT, प्रति शेयर लाभ

उमसत्ज़, EBIT और प्रति शेयर लाभ

प्रति शेयर उमसत्ज़

प्रति शेयर EBIT

प्रति शेयर आय

अनुमानित मान

ChemoCentryx बिक्री, लाभ और EBIT प्रति शेयर इतिहास

ChemoCentryx शेयर और शेयर विश्लेषण

अपने जीवन के सबसे अच्छे निवेश करो

ChemoCentryx Fair Value के अनुसार मूल्यांकन

Fair Value

Fair Value की समझ

आय-आधारित Fair Value

राजस्व-आधारित Fair Value

लाभांश-आधारित Fair Value

अपेक्षाएँ और अनुमान

तुलनात्मक विश्लेषण

ChemoCentryx का मूल्यांकन ऐतिहासिक P/E अनुपात, EBIT और P/S अनुपात के अनुसार

अपने जीवन के सबसे अच्छे निवेश करो

ChemoCentryx संख्या शेयर

उमसत्ज़, EBIT और प्रति शेयर लाभ

प्रति शेयर उमसत्ज़

प्रति शेयर EBIT

प्रति शेयर आय

अनुमानित मान

अपने जीवन के सबसे अच्छे निवेश करो

ChemoCentryx आय अनुमान

ChemoCentryx अर्निंग सरप्राइजेस

ChemoCentryx शेयर शेयरधारकों की संरचना

ChemoCentryx प्रबंधन और पर्यवेक्षण मंडल

Dr. Thomas Schall

Mr. Tausif Butt

Ms. Susan Kanaya

Dr. Markus Cappel

Dr. Rita Jain

टिकर
CCXI

ISIN
US16383L1061

WKN
A0NBM2